{"@context":{"@vocab":"https://cir.nii.ac.jp/schema/1.0/","rdfs":"http://www.w3.org/2000/01/rdf-schema#","dc":"http://purl.org/dc/elements/1.1/","dcterms":"http://purl.org/dc/terms/","foaf":"http://xmlns.com/foaf/0.1/","prism":"http://prismstandard.org/namespaces/basic/2.0/","cinii":"http://ci.nii.ac.jp/ns/1.0/","datacite":"https://schema.datacite.org/meta/kernel-4/","ndl":"http://ndl.go.jp/dcndl/terms/","jpcoar":"https://github.com/JPCOAR/schema/blob/master/2.0/"},"@id":"https://cir.nii.ac.jp/crid/1363670319471702144.json","@type":"Article","productIdentifier":[{"identifier":{"@type":"DOI","@value":"10.1128/aac.01802-13"}},{"identifier":{"@type":"URI","@value":"https://journals.asm.org/doi/pdf/10.1128/AAC.01802-13"}}],"dc:title":[{"@value":"Antimicrobial Activity of Ceftolozane-Tazobactam Tested against Enterobacteriaceae and Pseudomonas aeruginosa with Various Resistance Patterns Isolated in U.S. Hospitals (2011-2012)"}],"description":[{"type":"abstract","notation":[{"@value":"<jats:title>ABSTRACT</jats:title>\n          <jats:p>\n            Ceftolozane/tazobactam, a novel antimicrobial agent with activity against\n            <jats:named-content xmlns:xlink=\"http://www.w3.org/1999/xlink\" content-type=\"genus-species\" xlink:type=\"simple\">Pseudomonas aeruginosa</jats:named-content>\n            (including drug-resistant strains) and other common Gram-negative pathogens (including most extended-spectrum-β-lactamase [ESBL]-producing\n            <jats:named-content xmlns:xlink=\"http://www.w3.org/1999/xlink\" content-type=\"genus-species\" xlink:type=\"simple\">Enterobacteriaceae</jats:named-content>\n            strains), and comparator agents were susceptibility tested by a reference broth microdilution method against 7,071\n            <jats:named-content xmlns:xlink=\"http://www.w3.org/1999/xlink\" content-type=\"genus-species\" xlink:type=\"simple\">Enterobacteriaceae</jats:named-content>\n            and 1,971\n            <jats:named-content xmlns:xlink=\"http://www.w3.org/1999/xlink\" content-type=\"genus-species\" xlink:type=\"simple\">P. aeruginosa</jats:named-content>\n            isolates. Isolates were collected consecutively from patients in 32 medical centers across the United States during 2011 to 2012. Overall, 15.7% and 8.9% of\n            <jats:named-content xmlns:xlink=\"http://www.w3.org/1999/xlink\" content-type=\"genus-species\" xlink:type=\"simple\">P. aeruginosa</jats:named-content>\n            isolates were classified as multidrug resistant (MDR) and extensively drug resistant (XDR), and 8.4% and 1.2% of\n            <jats:named-content xmlns:xlink=\"http://www.w3.org/1999/xlink\" content-type=\"genus-species\" xlink:type=\"simple\">Enterobacteriaceae</jats:named-content>\n            were classified as MDR and XDR. No pandrug-resistant (PDR)\n            <jats:named-content xmlns:xlink=\"http://www.w3.org/1999/xlink\" content-type=\"genus-species\" xlink:type=\"simple\">Enterobacteriaceae</jats:named-content>\n            isolates and only one PDR\n            <jats:named-content xmlns:xlink=\"http://www.w3.org/1999/xlink\" content-type=\"genus-species\" xlink:type=\"simple\">P. aeruginosa</jats:named-content>\n            isolate were detected. Ceftolozane/tazobactam was the most potent (MIC\n            <jats:sub>50/90</jats:sub>\n            , 0.5/2 μg/ml) agent tested against\n            <jats:named-content xmlns:xlink=\"http://www.w3.org/1999/xlink\" content-type=\"genus-species\" xlink:type=\"simple\">P. aeruginosa</jats:named-content>\n            and demonstrated good activity against 310 MDR strains (MIC\n            <jats:sub>50/90</jats:sub>\n            , 2/8 μg/ml) and 175 XDR strains (MIC\n            <jats:sub>50/90</jats:sub>\n            , 4/16 μg/ml). Ceftolozane/tazobactam exhibited high overall activity (MIC\n            <jats:sub>50/90</jats:sub>\n            , 0.25/1 μg/ml) against\n            <jats:named-content xmlns:xlink=\"http://www.w3.org/1999/xlink\" content-type=\"genus-species\" xlink:type=\"simple\">Enterobacteriaceae</jats:named-content>\n            and retained activity (MIC\n            <jats:sub>50/90</jats:sub>\n            , 4/>32 μg/ml) against many 601 MDR strains but not against the 86 XDR strains (MIC\n            <jats:sub>50</jats:sub>\n            , >32 μg/ml). Ceftolozane/tazobactam was highly potent (MIC\n            <jats:sub>50/90</jats:sub>\n            , 0.25/0.5 μg/ml) against 2,691\n            <jats:named-content xmlns:xlink=\"http://www.w3.org/1999/xlink\" content-type=\"genus-species\" xlink:type=\"simple\">Escherichia coli</jats:named-content>\n            isolates and retained good activity against most ESBL-phenotype\n            <jats:named-content xmlns:xlink=\"http://www.w3.org/1999/xlink\" content-type=\"genus-species\" xlink:type=\"simple\">E. coli</jats:named-content>\n            isolates (MIC\n            <jats:sub>50/90</jats:sub>\n            , 0.5/4 μg/ml), but activity was low against ESBL-phenotype\n            <jats:named-content xmlns:xlink=\"http://www.w3.org/1999/xlink\" content-type=\"genus-species\" xlink:type=\"simple\">Klebsiella pneumoniae</jats:named-content>\n            isolates (MIC\n            <jats:sub>50/90</jats:sub>\n            , 32/>32 μg/ml), explained by the high rate (39.8%) of meropenem coresistance observed in this species phenotype. In summary, ceftolozane/tazobactam demonstrated high potency and broad-spectrum activity against many contemporary\n            <jats:named-content xmlns:xlink=\"http://www.w3.org/1999/xlink\" content-type=\"genus-species\" xlink:type=\"simple\">Enterobacteriaceae</jats:named-content>\n            and\n            <jats:named-content xmlns:xlink=\"http://www.w3.org/1999/xlink\" content-type=\"genus-species\" xlink:type=\"simple\">P. aeruginosa</jats:named-content>\n            isolates collected in U.S. medical centers. Importantly, ceftolozane/tazobactam retained potency against many MDR and XDR strains.\n          </jats:p>"}]}],"creator":[{"@id":"https://cir.nii.ac.jp/crid/1383670319471702144","@type":"Researcher","foaf:name":[{"@value":"David J. Farrell"}],"jpcoar:affiliationName":[{"@value":"JMI Laboratories, North Liberty, Iowa, USA"},{"@value":"Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, Ontario, Canada"}]},{"@id":"https://cir.nii.ac.jp/crid/1383670319471702147","@type":"Researcher","foaf:name":[{"@value":"Robert K. Flamm"}],"jpcoar:affiliationName":[{"@value":"JMI Laboratories, North Liberty, Iowa, USA"}]},{"@id":"https://cir.nii.ac.jp/crid/1383670319471702146","@type":"Researcher","foaf:name":[{"@value":"Helio S. Sader"}],"jpcoar:affiliationName":[{"@value":"JMI Laboratories, North Liberty, Iowa, USA"},{"@value":"Division of Infectious Diseases, Federal University of São Paulo, São Paulo, SP, Brazil"}]},{"@id":"https://cir.nii.ac.jp/crid/1383670319471702145","@type":"Researcher","foaf:name":[{"@value":"Ronald N. Jones"}],"jpcoar:affiliationName":[{"@value":"JMI Laboratories, North Liberty, Iowa, USA"},{"@value":"Tufts University School of Medicine, Boston, Massachusetts, USA"}]}],"publication":{"publicationIdentifier":[{"@type":"PISSN","@value":"00664804"},{"@type":"EISSN","@value":"10986596"}],"prism:publicationName":[{"@value":"Antimicrobial Agents and Chemotherapy"}],"dc:publisher":[{"@value":"American Society for Microbiology"}],"prism:publicationDate":"2013-12","prism:volume":"57","prism:number":"12","prism:startingPage":"6305","prism:endingPage":"6310"},"reviewed":"false","dc:rights":["https://journals.asm.org/non-commercial-tdm-license"],"url":[{"@id":"https://journals.asm.org/doi/pdf/10.1128/AAC.01802-13"}],"createdAt":"2013-10-08","modifiedAt":"2022-02-21","relatedProduct":[{"@id":"https://cir.nii.ac.jp/crid/1050287297240453632","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"Efficacy and Pharmacokinetics of the Combination of OP0595 and Cefepime in a Mouse Model of Pneumonia Caused by Extended-Spectrum-Beta-Lactamase-Producing Klebsiella pneumoniae"}]}],"dataSourceIdentifier":[{"@type":"CROSSREF","@value":"10.1128/aac.01802-13"},{"@type":"CROSSREF","@value":"10.1128/aac.00828-17_references_DOI_5l6YBiWUNq8sJJzRF0qpUMCItuP"}]}